Abstract
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD) have a syndemic relationship with shared risk factors and complex interplay between genetic, environmental, socioeconomic, and pathophysiological mechanisms. CVD is among the most common comorbidities in patients with COPD and vice versa. Patients with COPD, irrespective of their disease severity, are at increased risk of CVD morbidity and mortality, driven in part by COPD exacerbations. Despite these known interrelationships, CVD is underestimated and undertreated in patients with COPD. Similarly, COPD is an independent risk-enhancing factor for adverse cardiovascular (CV) events, yet it is not incorporated into current CV risk assessment tools, leading to under-recognition and undertreatment. There is a pressing need for systems change in COPD management to move beyond symptom control towards a comprehensive cardiopulmonary disease paradigm with proactive prevention of exacerbations and adverse cardiopulmonary outcomes and mortality. However, there is a dearth of evidence defining optimal cardiopulmonary care pathways. Fortunately, there is a precedent to support systems-level change in the field of diabetes, which evolved from glycemic control to comprehensive multi-organ risk assessment and management. Key elements included integrated multidisciplinary care, intensive risk factor management, coordination between primary and specialist care, care pathways and protocols, education and self management, and disease-modifying therapies. This commentary article draws parallels between the cardiometabolic and cardiopulmonary paradigms and makes a case for systems change towards multidisciplinary, integrated cardiopulmonary care, using the evolution in diabetes care as a potential framework.
Avoid common mistakes on your manuscript.
Commentary
Background
Over one-third of patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease (CVD), including atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), and arrhythmia [1,2,3,4,5,6,7]. COPD and CVD have a syndemic relationship, clustering through shared risk factors and biological interactions that exacerbate the prognosis and burden of disease [8, 9]. Health systems are dominated by single-disease frameworks, siloed specialties, and fragmented systems of care [8]. While integrated cardiopulmonary care has been proposed, the concept has gained limited traction in routine clinical practice [8]. This likely reflects the historic single-organ disease control epistemology, coupled with a lack of perceived benefit and the challenges of health service reorganization. However, there is strong precedent for the evolution of inter-specialty care to follow, namely the transformation of diabetes from an endocrine-focused model to the cardio-renal-metabolic disease management paradigm [10,11,12]. In this commentary article, we draw parallels between the cardiometabolic and cardiopulmonary paradigms, and ask what evidence is needed to support the transformation.
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
COPD and CVD Pathophysiological Mechanisms
All the major cardiovascular (CV) risk factors cluster in patients with COPD, including smoking, hypertension, dyslipidemia, diabetes, obesity, and physical inactivity [13,14,15,16]. Many of these are modifiable and thus represent opportunities for interventions that could improve patient outcomes. However, there is a growing body of evidence pointing to complex biological, physical/environmental, and socioeconomic interconnections between CVD and COPD, suggesting that the interplay between cardiopulmonary diseases cannot be attributed to interrelated risk factors alone [14].
COPD and CVD are both chronic inflammatory disorders. COPD may promote accelerated atherosclerosis through ‘spillover’ of inflammatory mediators from the lungs into the bloodstream [17], leading to changes in the microvascular environment that can result in rupture of susceptible plaques. In parallel, inflammatory mediators can promote hypercoagulability leading to increased thromboembolic risk [18], particularly in patients with pre-existing thrombotic risk factors such as atrial fibrillation (AF), highlighting the complex interplay between those mechanisms. Genetic and/or early life environmental factors in individuals with COPD may incrementally contribute to increased risk of ASCVD via pathophysiological mechanisms that remain poorly understood [19].
Similarly, there are multiple intertwined explanations for the increased risk of HF and arrhythmia in individuals with COPD. For example, myocardial contraction can be directly inhibited by airway inflammation, while pulmonary artery pressure and right heart strain can both be increased by chronic low-grade hypoxia induced by COPD [20, 21]. At the same time, dynamic hyperinflation and increased intrathoracic pressure may contribute to diastolic dysfunction and HF decompensation via impaired ventricular filling [22]. With respect to cardiac arrhythmias, the biventricular impairment of preload, afterload, and contractility both reduces cardiac output and increases atrial strain, and metabolic changes can exacerbate atrial hemodynamic effects to precipitate AF [23].
COPD is a CVD Risk-Enhancing Factor Across the Spectrum of Disease Severity
In addition to the well-defined mechanistic pathways linking COPD and CVD, multiple sectors of observational evidence suggest a significant causal relationship between the two. Reduced forced expiratory volume in one second (FEV1) in the general population is strongly associated with incident CVD and cardiovascular mortality, independent of smoking exposure and concurrent CV risk factors [24]. COPD is known to be a powerful independent predictor of incident and prevalent CVD. In a recent retrospective population-based cohort study including ∼5.8 million individuals without CVD in Canada, those with COPD had a 25% increased rate of incident CVD events after adjustment for traditional risk factors [adjusted hazard ratio (aHR) 1.25; 95% confidence interval (CI) 1.23–1.27] [25]. Similarly, in a meta-analysis of 29 datasets, patients with COPD were more likely to have prevalent CVD compared with the non-COPD population [odds ratio (OR) 2.46; 95% CI 2.02–3.00; p < 0.0001)], including a two to three times higher risk of ischemic heart disease (IHD), arrhythmia, HF, and vascular disease [26].
Once CVD is established, COPD remains an independent predictor of adverse CV events [27], irrespective of COPD severity, which is in part driven by acute exacerbations of COPD [28]. However, it must be recognized that the observational associations are significantly attenuated in studies with more comprehensive multivariable adjustment, emphasizing the importance of common risk factors in explaining the coexistence of cardio metabolic comorbidities and COPD [29,30,31,32].
The Precedent of Evolving Cardio-Renal-Metabolic Care
Although diabetes was initially considered a coronary heart disease ‘risk equivalent’ [33], subsequent meta-analyses indicated that diabetes did not convey the same magnitude of risk as established coronary disease [34]. Improvement in glycemic control certainly contributed to this reduction in risk. However, the multidisciplinary organization of care and intensive CV risk factor management in diabetes also significantly improved health outcomes prior to contemporary disease-modifying therapies [35,36,37]. Diabetes treatment initially focused on controlling hyperglycemia, with the subsequent recognition that this in turn reduced end-organ, predominantly microvascular, damage [10, 12]. The approach evolved, recognizing diabetes as a major ASCVD risk factor, and the importance of concurrent ASCVD risk factor control to improve outcomes [10,11,12, 38]. Interdisciplinary teams implemented comprehensive multi-organ disease management, including routine assessment and screening of eyes, feet, kidneys, cardiac risk factors, and disease [10,11,12]. Intensive as opposed to standard risk factor management followed (e.g., blood pressure, lipids) [10, 12] alongside systematic application of evidence-based, non-endocrine, disease-modifying treatments, including angiotensin-converting enzyme inhibitors (ACEis), angiotensin II receptor blockers (ARBs), and statins [10,11,12, 39]. Only more recently were sodium glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) introduced [10,11,12, 39]. The key elements of this evolution are summarized in Table 1 and provide a framework for integrated cardiopulmonary care (Fig. 1).
Proposed steps to adapt key concepts of integrated multidisciplinary cardiometabolic care to a cardiopulmonary disease paradigm. ACEi angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, ASCVD atherosclerotic cardiovascular disease, BP blood pressure, COPD chronic obstructive pulmonary disease, CP cardiopulmonary, CV cardiovascular, GLP-1 glucagon-like peptide 1, HF heart failure, SGLT2i sodium-glucose cotransporter-2 inhibitor, SITT single inhaler triple therapy
ASCVD Risk is Underestimated in Patients with COPD
Primary prevention strategies are founded on risk assessment. Knowledge of the 10-year risk for ASCVD identifies patients in higher-risk groups who are likely to have greater net benefit and lower number needed to treat (NNT) from both statins and antihypertensive therapy [40]. Prevention guidelines recommend risk estimators such as the pooled cohort equations, QRISK, or SCORE2 to inform shared decision-making between clinicians and patients [41, 42]. The risk scores were developed and validated in general populations whose baseline risk is lower than selected populations, such as those with COPD. None of the CVD risk prediction tools were developed or validated in patients with COPD or include COPD as a predictor, and consequently markedly underestimate risk. In a recent retrospective cohort study, the 10-year risk of incident CVD in primary care patients with COPD was 52% higher than predicted by the QRISK score, and the discrepancy between predicted and observed CV risk was even more striking among individuals with COPD age 65 years or younger (82%) [19]. Moreover, patients with ‘borderline’ and ‘intermediate’ risk when applying current tools are considered for statin therapy in the presence of ‘risk-enhancing’ factors, which include chronic kidney disease and systemic inflammatory conditions. Notably, COPD is not currently included in guidelines as a risk-enhancing factor. Risk prediction models may significantly underestimate ASCVD risk in patients with COPD due to several factors (Fig. 2). First, there may be shared unmeasured risk factors in patients with COPD and CVD. Second, COPD may directly cause CVD through the aforementioned mechanistic pathways. Finally, models are developed for an average person in the general population but patients with COPD have higher baseline ASCVD risk.
High Prevalence Yet Under-Recognition of Cardiopulmonary Disease
Screening is most cost-effective when there is a high unrecognized disease burden and absolute risk, detectable preclinical phase, accurate and acceptable tests, and disease-modifying therapies [43]. The cardiopulmonary continuum fulfills all these criteria. Through shared pathophysiology and risk factors, CVD is among the most common comorbidities in patients with COPD, and vice versa. In a systematic review and meta-analysis of 29 unique datasets, up to 64% of patients with COPD had IHD, 41% HF, 29% arrhythmias, and 13% stroke [26]. COPD is similarly prevalent in patients with CVD, although it is often undiagnosed [44]. Indeed, COPD or airflow limitation on spirometry has been reported in up to 34% of patients with IHD, 25–30% with HF, 13% with AF, and 10–12% with stroke [44,45,46]. In addition, through shared symptoms including dyspnea and exercise intolerance, CVD and COPD are also among the most unrecognized respective comorbidities. For example, undiagnosed HF is present in up to one-fifth of patients with COPD [47], and spirometry identifies undiagnosed COPD in one-quarter to one-third of patients with a broad range of CVD [48, 49].
COPD is a Risk-Enriched Population
Cardiovascular morbidity and mortality in patients with COPD is similar to that of pulmonary and cancer-related disease; overall, around one-third of deaths are attributable to the respective causes [50]. However, CVD is the leading cause of death in patients with milder COPD by Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification, while respiratory death assumes a greater proportion with increased severity of airflow obstruction [51]. This has significant implications in terms of value and cost-effectiveness of screening and treatment. Not only do patients with milder COPD represent the largest population but also the population with the greatest longevity, and therefore potential long-term gain in quality-adjusted life years.
CV Risk Exists Across the Spectrum of COPD
The fallacy of ‘stable HF’ is increasingly recognized, since, even in the absence of overt symptoms and signs, it is almost always a progressive disease with neurohormonal activation, structural remodeling, and inherent risk of decompensation and future adverse events [52]. The Canadian Cardiovascular Society guidelines for the management of HF specifically counter that the term ‘stable’ is “not considered to be clinically appropriate because of the inherent risk of future clinical events” [53]. Moreover, ‘stable’ implies good prognosis, which lowers risk perception by both patients and providers, contributing to therapeutic inertia and withholding of disease-modifying therapies. The same principles may theoretically be extended to COPD, where even patients with milder symptoms and infrequent exacerbations experience progressive lung function decline [54] and have an elevated risk of cardiovascular morbidity and mortality [51, 55].
The risk of cardiovascular events is elevated even during periods of clinically stable COPD [56, 57]. In a prospective study of 287 people with COPD who were prescribed guideline-recommended optimal COPD therapy who had not had a recent exacerbation or any prior cardiovascular event, the incidence of myocardial infarction (27%), IHD or angina (23%), peripheral artery disease requiring surgery (27%), and stroke (23%), were high over a median follow-up of 65 months [56].
Notwithstanding the need to optimize management across the spectrum of COPD severity, the risk for CV events is particularly heightened after exacerbations, making it a key driver of morbidity and mortality in individuals with COPD [28, 58,59,60]. Although the risks of myocardial infarction and stroke are highest in the first 30 days following a moderate or severe exacerbation, the period of elevated risk persists over time to at least 1 year [28, 58,59,60,61,62,63,64,65,66] (see Table S1 in the electronic supplementary material). Thus, it appears that damage from exacerbation extends beyond the lungs, and preventing exacerbations has important morbidity and mortality implications for both the pulmonary and CV systems.
Undertreatment and Opportunity to Improve CV Risk and Disease Control
Despite the high prevalence and burden of CVD in people with COPD and the availability of evidence-based primary and secondary CV risk reduction treatments [67], there is a concerning level of under treatment of CV risk factors and CVD in people with COPD [29, 68,69,70]. Recent evidence is shifting from counting comorbidities in COPD to measuring how they are monitored, treated, and controlled. In a cross-sectional study of over 30,000 patients with COPD in Canadian primary care, the major CV risk factors when defined using objective measures including laboratory results were more common than anticipated, including hypertension (52%), dyslipidemia (62%), diabetes (25%), obesity (41%), and smoking (41%) [16]. More than half of patients (54%) had a high Framingham risk score. Monitoring was suboptimal, and guideline-recommended targets for the above-mentioned risk factors were only achieved in 61%, 47%, 57%, 11%, and 12% of patients, respectively. Simple CV therapies including ACEi and statins were notably underused.
Findings are similar for secondary prevention. Patients admitted for major CV events who have COPD are significantly less likely than those without COPD to undergo invasive cardiac investigations or procedures (e.g., coronary angiography, percutaneous coronary intervention), and are less likely to be discharged on established secondary prevention medications such as antiplatelets, beta-blockers, statins, ACEis, and ARBs [29, 68,69,70]. This evidence supports the existence of a classic risk–treatment paradox in people with cardiopulmonary disease, wherein those with the greatest absolute risk of poor outcomes are the least likely to be treated with established life-saving therapies.
Undertreatment and Opportunity to Improve COPD Disease Control
In the last few decades, there has been a dramatic reduction in CVD mortality rates in Western countries, of which 47% has been attributed to the application of evidence-based medical and surgical treatments and 44% to improvements in CV risk factors, including reductions in cholesterol and blood pressure [71]. Although reductions in mortality rates due to COPD have seen a less dramatic decline owing in part to the aging population [72], mortality reduction is nonetheless an achievable goal of COPD management.
Reductions in all-cause and CV-related mortality have been demonstrated with optimal treatment of COPD that includes smoking cessation, pulmonary rehabilitation, physical activity, self-management, vaccination, and, more recently, single-inhaler triple therapy (SITT) which includes a long-acting muscarinic antagonist (LAMA), a long-acting beta-2 agonist (LABA), and an inhaled corticosteroid (ICS) [73, 74]. Two recent large, randomized, controlled trials (RCTs) compared SITT to dual therapy in nearly 19,000 patients with moderate-to-severe COPD. Over just 52 weeks in both trials, SITT reduced not only the primary endpoint of annualized rate of exacerbations but also the secondary endpoints of CV and all-cause mortality [75, 76]. These studies—ETHOS (n = 8509) and IMPACT (n = 10,355)—suggest that mortality reductions with SITT are at least as robust as smoking cessation and established cardioprotective and cardio-renal-metabolic treatments (Fig. 3). The relative NNT to prevent one death from any cause for SITT is 80 for the ETHOS study [75] and 121 for IMPACT [76]; these findings are equal or better than statin therapy in patients with IHD (NNT 164) [77] and SGLT-2is for type 2 diabetes (NNT 120) [78]. SITT is therefore a key guideline directed therapy to improve outcomes including all-cause mortality in appropriately selected patients with COPD.
Absolute reductions in all-cause mortality with SITT, smoking cessation, and secondary preventive CVD treatments [75, 78, 89]. Figure originally published by and used with permission from Dove Medical Press Ltd. International Journal of COPD 2021;16:499–517 (adapted). a Pooled analysis of adverse events leading to a fatal outcome (safety population). b On- and off-treatment deaths in post hoc analysis with additional vital status follow-up (vital status available for 99.6% of patients at nominal Week 52). c Analysis included all observed data regardless of whether patients continued to receive their assigned treatment. BDP beclomethasone dipropionate, BUD budesonide, CVD cardiovascular disease, FF fluticasone furoate, FORM formoterol, GLY glycopyrronium, ICS inhaled corticosteroid, IND indacaterol, SITT single inhaler triple therapy, UMEC umeclidinium, VI vilanterol
Consideration of COPD Phenotypes, Endotypes, and Treatable Traits
Complex COPD phenotypes and endotypes, which have evolved into the concept of clinically relevant treatable traits as a strategy of personalized medicine [79,80,81,82], also warrant consideration within an integrated approach to cardiopulmonary care. Treatable traits in COPD may be categorized into pulmonary, extrapulmonary, and behavioral domains [79]. Pulmonary traits have traditionally been the dominant domain and include lung function/airflow limitation and airway inflammation among other factors [79, 81, 82]. Extrapulmonary traits include comorbidities and exercise intolerance, and behavioral traits include risk factors and behaviors that worsen disease symptoms and outcomes, as well as suboptimal disease self-management (e.g., poor medication adherence and administration techniques) [79]. There is benefit in implementing identification and treatment of traits into practice in patients with severe asthma and COPD, although less so for patients with mild disease at this time [79]. The magnitude of CV risk varies, although it is consistently elevated in different COPD disease phenotypes, suggesting that phenotypes and treatable traits may be helpful in developing integrated models of cardiopulmonary care [83].
As suggested by a multidisciplinary panel of experts, clinician professional development and skill enhancement, as well as funding for multidisciplinary services, could contribute to implementation of treatable traits in practice [79].
Need for Systems Change
The evidence supporting cardiopulmonary interrelationships, risk factors, and treatments with mortality benefits is incontrovertible, yet there is a dearth of evidence defining optimal care pathways for cardiopulmonary health. Dedicated RCTs to address this knowledge gap are unfortunately unlikely for several reasons, including limited funding opportunities, the challenges of testing health service interventions, and the common exclusion of patients with comorbidity from trials [84].
The care paradigm and management guidelines for diabetes shifted without dedicated trials rigorously examining different multidisciplinary models of care; therefore, the question of whether dedicated RCTs are necessary to support a shift in cardiopulmonary management is worth exploring. COPD guidance documents including the GOLD strategy acknowledge the need to recognize and address comorbidities in patients with COPD, and specifically note that CVD is a common and important comorbidity among patients with COPD, but recommendations or algorithms for screening, assessment, risk factor and disease management, and multidisciplinary care have not yet been developed [85, 86].
The central components of systems change include integrated multidisciplinary care connecting primary and specialist care, clinician and provider training, referral networks, individual case management and continuity of care, information and data sharing, care pathways and protocols, performance reporting and accountability, and education and promotion of self-management. The opportunity for improvement was highlighted in a recent multicenter, cluster-randomized, controlled trial of proactive early detection of CVD in patients with diabetes or COPD in primary care in the Netherlands [87]. A strategy including a symptom questionnaire, physical examination, N-terminal prohormone of brain natriuretic peptide, and electrocardiogram, more than doubled the number of new diagnoses of HF, AF, and coronary artery disease [87]. In the diabetes setting, interdisciplinary diabetes care teams are associated with improved health outcomes and achievement of targets for disease management [35,36,37]. Certified diabetes educators have played a key role in advancing this paradigm of patient-centered chronic cardio-renal-metabolic disease management [88]. In COPD, no such trials have been conducted. However, certified respiratory educators and respiratory technicians are well positioned to play a similar role, but education on CV risk management will be needed. Future endeavors such as expert consensus statements should aim to address gaps in our current models of care and offer guidance on how best to approach management of cardiopulmonary risk.
Conclusions
Systems change is difficult to achieve in any field, as there are numerous barriers and considerable inertia to overcome, especially when multiple disciplines are involved. Encouragingly, there is precedent for the successful implementation of systems-level change and associated improvements in morbidity and mortality by applying a multi-organ, multidisciplinary approach, as exemplified by the evolution of diabetes care. It is time for cardiopulmonary management to move beyond symptom control and reactive management to proactive prevention of exacerbations and adverse cardiopulmonary outcomes and mortality by embracing a paradigm shift to multi-organ, integrated care.
References
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233–9.
Pauwels RA, Löfdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–53.
Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320(7245):1297–303.
Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–89.
McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax. 2007;62(5):411–5.
Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180(10):948–55.
Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–54.
Hawkins NM, Virani S, Ceconi C. Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. Eur Heart J. 2013;34(36):2795–803.
Fabbri LM, Celli BR, Agustí A, Criner GJ, Dransfield MT, Divo M, et al. COPD and multimorbidity: recognising and addressing a syndemic occurrence. Lancet Respir Med. 2023;11(11):1020–34.
Canada D. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2018;42(Suppl. 1):S1-306.
Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm—2020 executive summary. Endocr Pr. 2020;26(1):107–39.
American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 46(Suppl. 1):S1–291.
Almagro P, Boixeda R, Diez-Manglano J, Gómez-Antúnez M, López-García F, Recio J. Insights into chronic obstructive pulmonary disease as critical risk factor for cardiovascular disease. Int J Chron Obstruct Pulmon Dis. 2020;15:755–64.
Khan SS, Kalhan R. Comorbid chronic obstructive pulmonary disease and heart failure: shared risk factors and opportunities to improve outcomes. Ann Am Thorac Soc. 2022;19(6):897–9.
Vanfleteren LEGW, Spruit MA, Groenen M, Gaffron S, van Empel VPM, Bruijnzeel PLB, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–35.
Hawkins NM, Peterson S, Ezzat AM, Vijh R, Virani SA, Gibb A, et al. Control of cardiovascular risk factors in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2022;19(7):1102–11.
Van Eeden S, Leipsic J, Paul Man SF, Sin DD. The relationship between lung inflammation and cardiovascular disease. Am J Respir Crit Care Med. 2012;186(1):11–6.
Kyriakopoulos C, Gogali A, Kostikas K, Konstantinidis A. Hypercoagulable state in COPD-a comprehensive literature review. Diagn Basel Switz. 2021;11(8):1447.
Amegadzie JE, Gao Z, Quint JK, Russell R, Hurst JR, Lee TY, et al. QRISK3 underestimates the risk of cardiovascular events in patients with COPD. Thorax [Internet]. 2023 Nov 27 [cited 2023 Nov 27]; https://thorax.bmj.com/content/early/2023/11/27/thorax-2023-220615
Wouters EFM, Groenewegen KH, Dentener MA, Vernooy JHJ. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc. 2007;4(8):626–34.
Suda K, Tsuruta M, Eom J, Or C, Mui T, Jaw JE, et al. Acute lung injury induces cardiovascular dysfunction: effects of IL-6 and budesonide/formoterol. Am J Respir Cell Mol Biol. 2011;45(3):510–6.
Alter P, Watz H, Kahnert K, Pfeifer M, Randerath WJ, Andreas S, et al. Airway obstruction and lung hyperinflation in COPD are linked to an impaired left ventricular diastolic filling. Respir Med. 2018;137:14–22.
Simons SO, Elliott A, Sastry M, Hendriks JM, Arzt M, Rienstra M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. Eur Heart J. 2021;42(5):532–40.
Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J. 2007;30(4):616–22.
Maclagan LC, Croxford R, Chu A, Sin DD, Udell JA, Lee DS, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort. Eur Respir J. 2023;62(2):2202364.
Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(8):631–9.
Li Y, Zheng H, Yan W, Cao N, Yan T, Zhu H, et al. The impact of chronic obstructive pulmonary disease on the prognosis outcomes of patients with percutaneous coronary intervention or coronary artery bypass grafting: A meta-analysis. Heart Lung J Crit Care. 2023;60:8–14.
Kunisaki KM, Dransfield MT, Anderson JA, Brook RD, Calverley PMA, Celli BR, et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. Am J Respir Crit Care Med. 2018 Jul 1;198(1):51–7.
Andell P, Koul S, Martinsson A, Sundström J, Jernberg T, Smith JG, et al. Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarction. Open Heart. 2014;1(1): e000002.
Yandrapalli S, Pandit M, Malik A, Gupta K, Nabors C, Jain D, et al. Impact of chronic obstructive pulmonary disease on heart failure hospitalizations after an acute myocardial infarction. Arch Med Sci Atheroscler Dis. 2023;8:e35-43.
Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, et al. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail. 2009;11(3):292–8.
Triest FJJ, Studnicka M, Franssen FME, Vollmer WM, Lamprecht B, Wouters EFM, et al. Airflow Obstruction and Cardio-metabolic Comorbidities. COPD. 2019;16(2):109–17.
Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.
Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med J Br Diabet Assoc. 2009;26(2):142–8.
Borgermans L, Goderis G, Van Den Broeke C, Verbeke G, Carbonez A, Ivanova A, et al. Interdisciplinary diabetes care teams operating on the interface between primary and specialty care are associated with improved outcomes of care: findings from the Leuven Diabetes Project. BMC Health Serv Res. 20091007th ed. 2009 Oct 7;9:179.
Renders CM, Valk GD, Griffin S, Wagner EH, Eijk JT, Assendelft WJ. Interventions to improve the management of diabetes mellitus in primary care, outpatient and community settings. Cochrane Database Syst Rev. 2001;2000(1):CD001481.
Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med. 2002 May;22(4 Suppl):15–38.
McGill M, Felton AM. New global recommendations: a multidisciplinary approach to improving outcomes in diabetes. Prim Care Diabetes. 20061219th ed. 2007 Feb;1(1):49–55.
Lipscombe L, Butalia S, Dasgupta K, Eurich DT, MacCallum L, Shah BR, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Can J Diabetes. 2020;44(7):575–91.
Lloyd-Jones DM, Braun LT, Ndumele CE, Smith SC, Sperling LS, Virani SS, et al. Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American heart association and American college of cardiology. Circulation. 2019;139(25):e1162–77.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation. 2019;140(11):e596-646.
SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439–54.
Dobrow MJ, Hagens V, Chafe R, Sullivan T, Rabeneck L. Consolidated principles for screening based on a systematic review and consensus process. CMAJ Can Med Assoc J J Assoc Medicale Can. 2018;190(14):E422–9.
Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016 Dec 1;194(11):1319–36.
Romiti GF, Corica B, Pipitone E, Vitolo M, Raparelli V, Basili S, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 2021;42(35):3541–54.
Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2018;5(4):685–94.
Rutten FH, Cramer MJM, Grobbee DE, Sachs APE, Kirkels JH, Lammers JWJ, et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005;26(18):1887–94.
Franssen FME, Soriano JB, Roche N, Bloomfield PH, Brusselle G, Fabbri LM, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med. 2016;194(5):568–76.
Soriano JB, Rigo F, Guerrero D, Yañez A, Forteza JF, Frontera G, et al. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest. 2010;137(2):333–40.
Berry CE, Wise RA. Mortality in COPD: causes, risk factors, and prevention. COPD. 2010;7(5):375–82.
Mannino DM, Doherty DE, Sonia BA. Global initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115–22.
Pascual-Figal D, Bayes-Genis A. The misperception of ‘stable’ heart failure. Eur J Heart Fail. 2018;20(10):1375–8.
Ezekowitz JA, O’Meara E, McDonald MA, Abrams H, Chan M, Ducharme A, et al. 2017 comprehensive update of the Canadian cardiovascular society guidelines for the management of heart failure. Can J Cardiol. 2017;33(11):1342–433.
Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768–74.
Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J. 2008;32(4):962–9.
Zagaceta J, Bastarrika G, Zulueta JJ, Colina I, Alcaide AB, Campo A, et al. Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respir Res. 2017;18(1):175.
Giezeman M, Sundh J, Athlin Å, Lisspers K, Ställberg B, Janson C, et al. Comorbid heart disease in patients with COPD is associated with increased hospitalization and mortality—a 15-year follow-up. Int J Chron Obstruct Pulmon Dis. 2023;18:11–21.
Rothnie KJ, Connell O, Müllerová H, Smeeth L, Pearce N, Douglas I, et al. Myocardial infarction and ischemic stroke after exacerbations of chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2018;15(8):935–46.
Donaldson GC, Hurst JR, Smith CJ, Hubbard RB, Wedzicha JA. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010;137(5):1091–7.
Løkke A, Hilberg O, Lange P, Ibsen R, Telg G, Stratelis G, et al. Exacerbations predict severe cardiovascular events in patients with COPD and stable cardiovascular disease-a nationwide, population-based cohort study. Int J Chron Obstruct Pulmon Dis. 2023;18:419–29.
Müllerová H, Marshall J, de Nigris E, Varghese P, Pooley N, Embleton N, et al. Association of COPD exacerbations and acute cardiovascular events: a systematic review and meta-analysis. Ther Adv Respir Dis. 2022;16:17534666221113648.
Dransfield MT, Criner GJ, Halpin DMG, Han MK, Hartley B, Kalhan R, et al. Time-dependent risk of cardiovascular events following an exacerbation in patients with chronic obstructive pulmonary disease: post hoc analysis from the IMPACT trial. J Am Heart Assoc. 2022;11(18): e024350.
Wang M, Lin EPY, Huang LC, Li CY, Shyr Y, Lai CH. Mortality of cardiovascular events in patients with COPD and preceding hospitalization for acute exacerbation. Chest. 2020;158(3):973–85.
Goto T, Shimada YJ, Faridi MK, Camargo CA, Hasegawa K. Incidence of acute cardiovascular event after acute exacerbation of COPD. J Gen Intern Med. 2018;33(9):1461–8.
Reilev M, Pottegård A, Lykkegaard J, Søndergaard J, Ingebrigtsen TS, Hallas J. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD. Respirol Carlton Vic. 2019;24(12):1183–90.
Portegies MLP, Lahousse L, Joos GF, Hofman A, Koudstaal PJ, Stricker BH, et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med. 2016 Feb 1;193(3):251–8.
Cao C, Wu Y, Xu Z, Lv D, Zhang C, Lai T, et al. The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality: a systematic review and meta-analysis of observational research. Sci Rep. 2015;10(5):16461.
Rothnie KJ, Smeeth L, Herrett E, Pearce N, Hemingway H, Wedzicha J, et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart Br Card Soc. 2015;101(14):1103–10.
Rasmussen DB, Bodtger U, Lamberts M, Nicolaisen SK, Sessa M, Capuano A, et al. Beta-blocker, aspirin, and statin usage after first-time myocardial infarction in patients with chronic obstructive pulmonary disease: a nationwide analysis from 1995 to 2015 in Denmark. Eur Heart J Qual Care Clin Outcomes. 2020;6(1):23–31.
Makam RCP, Erskine N, McManus DD, Lessard D, Gore JM, Yarzebski J, et al. Decade Long Trends (2001–2011) in the Use of Evidence-based Medical Therapies at the Time of Hospital Discharge for Patients Surviving Acute Myocardial Infarction. Am J Cardiol. 2016;118(12):1792–7.
Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in cardiovascular mortality: possible causes and implications. Circ Res. 2017;120(2):366–80.
Burney P, Patel J, Newson R, Minelli C, Naghavi M. Global and regional trends in chronic obstructive pulmonary disease mortality 1990–2010. Eur Respir J. 2015;45(5):1239–47.
Celi A, Latorre M, Paggiaro P, Pistelli R. Chronic obstructive pulmonary disease: moving from symptom relief to mortality reduction. Ther Adv Chronic Dis. 2021;13(12):20406223211014028.
Ryrsø CK, Godtfredsen NS, Kofod LM, Lavesen M, Mogensen L, Tobberup R, et al. Lower mortality after early supervised pulmonary rehabilitation following COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med. 2018;18(1):154.
Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021 Mar 1;203(5):553–64.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–16.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet Lond Engl. 1994 Nov 19;344(8934):1383–9.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
Papi A, Faner R, Pavord I, Baraldi F, McDonald VM, Thomas M, et al. From treatable traits to GETomics in airway disease: moving towards clinical practice. Eur Respir Rev Off J Eur Respir Soc. 2024;33(171): 230143.
Agusti A, Ambrosino N, Blackstock F, Bourbeau J, Casaburi R, Celli B, et al. COPD: Providing the right treatment for the right patient at the right time. Respir Med. 2023;207: 107041.
Agusti A, Gibson PG, McDonald VM. Treatable traits in airway disease: from theory to practice. J Allergy Clin Immunol Pract. 2023;11(3):713–23.
Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J. 2016;47(2):410–9.
Cobb K, Kenyon J, Lu J, Krieger B, Perelas A, Nana-Sinkam P, et al. COPD is associated with increased cardiovascular disease risk independent of phenotype. Respirol Carlton Vic. 2024 Jul 17 [online ahead of print].
Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis. 2018;12:1753465817750524.
Bon J. Acute chronic obstructive pulmonary disease exacerbations and cardiovascular risk: a time for lung disease-specific screening strategies. Ann Am Thorac Soc. 2018;15(8):913–5.
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report) [Internet]. 2023 [cited 2023 Jun 13]. Available from: https://goldcopd.org/wp-content/uploads/2023/03/GOLD-2023-ver-1.3-17Feb2023_WMV.pdf
Groenewegen A, Zwartkruis VW, Rienstra M, Zuithoff NPA, Hollander M, Koffijberg H, et al. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial. Lancet Public Health. 2024;9(2):e88-99.
Burke SD, Sherr D, Lipman RD. Partnering with diabetes educators to improve patient outcomes. Diabetes Metab Syndr Obes Targets Ther. 2014;12(7):45–53.
Bourbeau J, Bafadhel M, Barnes NC, Compton C, Di Boscio V, Lipson DA, et al. Benefit/risk profile of single-inhaler triple therapy in COPD. Int J Chron Obstruct Pulmon Dis. 2021;16:499–517.
Medical Writing, Editorial, and Other Assistance
Ari Mendell, MSc, PhD at Compass Leaf Medical Communications Inc. (Guelph, Ontario, Canada) and Christina Clark, MSc at CC Medical Writing Inc. (Mansonville, Quebec, Canada) provided professional medical writing services in the form of editorial and administrative support for this manuscript. This support was funded by AstraZeneca Canada.
Funding
Funding was provided by AstraZeneca Canada to pay for the journal’s rapid service fee. Funders did not influence the content of the manuscript. AstraZeneca did not provide any honoraria to the authors for the purpose of the development of this manuscript.
Author information
Authors and Affiliations
Contributions
All authors contributed to the article conception and design. The manuscript was initially drafted by Nathaniel M Hawkins and Mohit Bhutani and multiple rounds of content review and revisions were undertaken with the full authorship group before article finalization. Nathaniel M Hawkins, Alan Kaplan, Dennis T Ko, Erika Penz, and Mohit Bhutani read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflicts of Interest
The authors disclose the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Nathaniel M Hawkins has received grants from AstraZeneca, and consulting fees and honoraria for presentations from AstraZeneca, Bayer, and Novartis. Alan Kaplan has received consulting fees and honoraria for presentations from ALK, AstraZeneca, Belus, Eisai, GSK, Idorsia Moderna, Merck Frosst, Pfizer, Sanofi, Trudel, and Valero, and he is a board member of the Family Physicians Airways Group of Canada and the Observational and Pragmatic Research Institute Respiratory Effectiveness Group. Alan Kaplan is an Editorial Board member of Pulmonary Therapy and was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Dennis T Ko has no conflicts to disclose. Erika Penz has received grants from the Canadian Institute of Health Research, Saskatchewan Health Research Foundation, AstraZeneca, and Sanofi, consulting fees from AstraZeneca, GlaxoSmithKline and Sanofi, and honoraria for presentations from AstraZeneca, GlaxoSmithKline, the Canadian Thoracic Society, and COVID Pharma, support for attending meetings from GlaxoSmithKline, she participates in Data Safety Monitoring or Advisory Boards for AstraZeneca, GlaxoSmithKline, and Sanofi, and is an executive board member of the Canadian Thoracic Society, a board member of the Canadian Institute of Health Research, a medical advisor to the Lung Cancer Screening Program, and co-chair of the National Senior Respiratory Fellows Symposium. Mohit Bhutani has received grants from AstraZeneca, GSK, Sanofi, and Mereo Pharma, consulting fees and honoraria from AstraZeneca, GSK, Sanofi, Valeo and Covis, support for attending meetings from AstraZeneca, GSK, and Sanofi, and is an executive board member of the Canadian Thoracic Society.
Ethical Approval
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Hawkins, N.M., Kaplan, A., Ko, D.T. et al. Is ‘Cardiopulmonary’ the New ‘Cardiometabolic’? Making a Case for Systems Change in COPD. Pulm Ther (2024). https://doi.org/10.1007/s41030-024-00270-2
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s41030-024-00270-2